Combretastatin A-1 phosphate (tetrasodium)

Combretastatin A-1 phosphate (OXi-4503) tetrasodium, a proagent of Combretastatin A-1, is a microtubule polymerization inhibitor that binds to the colchicine-binding site of tubulin. Combretastatin A-1 phosphate tetrasodium inhibits the Wnt/β-catenin pathway through tubulin depolymerization mediated AKT deactivation. Combretastatin A-1 phosphate tetrasodium exhibits anti-tumor and anti-vascular effects[1][2][3].

Product Specifications

CAS Number

[288847-34-7]

Product Name Alternative

OXi-4503 (tetrasodium)

UNSPSC

12352005

Target

Microtubule/Tubulin; Wnt

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Solubility

10 mM in DMSO

Smiles

O=P(O[Na])(O[Na])OC1=C(C(OC)=CC=C1/C=C\C2=CC(OC)=C(C(OC)=C2)OC)OP(O[Na])(O[Na])=O

Molecular Formula

C18H18Na4O12P2

Molecular Weight

580.23

References & Citations

[1]Stratford MRL, et, al. Quantitative determination of the anticancer prodrug combretastatin A1 phosphate (OXi4503, CA1P), the active CA1 and its glucuronide metabolites in human urine and of CA1 in plasma by HPLC with mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 1;898:1-6.|[2]Mao J, et, al. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway. Cancer Lett. 2016 Sep 28;380 (1) :134-43.|[3]Holwell SE, et, al. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Anticancer Res. Nov-Dec 2002;22 (6C) :3933-40.